Optilume BPH Catheter System
Urotronic, Inc. · Decision date Dec 15, 2025
What did the FDA approve?
FDA records P220029/S003 as a supplement to PMA P220029, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Dec 15, 2025.
FDA approval order statement
Approval of the revised protocol for the post-approval study (PAS)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Dec 15, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P220029/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Urotronic, Inc.
- Product code
- QXB
- Decision code
- APPR
- Decision date
- Dec 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug coated prostatic dilation catheter for benign prostatic hyperplasia.
- Applicant
- Urotronic, Inc.
- Product code
- QXB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220029/S003 received
Application receipt date recorded by FDA.
P220029/S004 · Related supplement
Optilume BPH Catheter System
P220029/S003 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P220029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optilume BPH Catheter SystemP220029/S004 | Urotronic, Inc. | PMA supplement | Dec 12, 2025 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Urotronic, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2495 Xenium Ln., Minneapolis, MN, 55449
Sources and methodology
- Original FDA record: P220029/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records